Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells

Elizabeth Half, Yunjie Sun, Frank A Sinicrope

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) is a transcriptional target and downstream effector of the ErbB-1 (EGFR) and ErbB-2 signaling pathways. We found that anti-EGFR and anti-ErbB-2 antibodies inhibited ERK phosphorylation and downregulated COX-2 protein expression in HCA-7 human colon carcinoma cells. Both antibodies also augmented the cytotoxic effects of the selective COX-2 inhibitor, NS-398. Inhibition of EGFR and ErbB-2 attenuated cell growth by increasing cell death, and the antibody combination suppressed cell growth to a greater extent than did either antibody alone. In conclusion, EGFR and ErbB-2 regulate ERK-mediated COX-2 expression and their selective inhibition enhanced NS-398-induced cell death. Cooperative inhibition of cell growth by EGFR and ErbB-2 blockade suggests the therapeutic potential of targeting multiple ErbB receptors.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalCancer Letters
Volume251
Issue number2
DOIs
StatePublished - Jun 28 2007

Fingerprint

Cyclooxygenase 2
Colonic Neoplasms
Survival
Antibodies
Cell Death
Growth
Cyclooxygenase 2 Inhibitors
Colon
Down-Regulation
Phosphorylation
Carcinoma
Proteins
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
Therapeutics

Keywords

  • Cetuximab
  • COX-2
  • EGFR
  • ErbB-2
  • NS-398
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. / Half, Elizabeth; Sun, Yunjie; Sinicrope, Frank A.

In: Cancer Letters, Vol. 251, No. 2, 28.06.2007, p. 237-246.

Research output: Contribution to journalArticle

@article{365b844c03364cffaa55da6a7d567087,
title = "Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells",
abstract = "Cyclooxygenase-2 (COX-2) is a transcriptional target and downstream effector of the ErbB-1 (EGFR) and ErbB-2 signaling pathways. We found that anti-EGFR and anti-ErbB-2 antibodies inhibited ERK phosphorylation and downregulated COX-2 protein expression in HCA-7 human colon carcinoma cells. Both antibodies also augmented the cytotoxic effects of the selective COX-2 inhibitor, NS-398. Inhibition of EGFR and ErbB-2 attenuated cell growth by increasing cell death, and the antibody combination suppressed cell growth to a greater extent than did either antibody alone. In conclusion, EGFR and ErbB-2 regulate ERK-mediated COX-2 expression and their selective inhibition enhanced NS-398-induced cell death. Cooperative inhibition of cell growth by EGFR and ErbB-2 blockade suggests the therapeutic potential of targeting multiple ErbB receptors.",
keywords = "Cetuximab, COX-2, EGFR, ErbB-2, NS-398, Trastuzumab",
author = "Elizabeth Half and Yunjie Sun and Sinicrope, {Frank A}",
year = "2007",
month = "6",
day = "28",
doi = "10.1016/j.canlet.2006.11.020",
language = "English (US)",
volume = "251",
pages = "237--246",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells

AU - Half, Elizabeth

AU - Sun, Yunjie

AU - Sinicrope, Frank A

PY - 2007/6/28

Y1 - 2007/6/28

N2 - Cyclooxygenase-2 (COX-2) is a transcriptional target and downstream effector of the ErbB-1 (EGFR) and ErbB-2 signaling pathways. We found that anti-EGFR and anti-ErbB-2 antibodies inhibited ERK phosphorylation and downregulated COX-2 protein expression in HCA-7 human colon carcinoma cells. Both antibodies also augmented the cytotoxic effects of the selective COX-2 inhibitor, NS-398. Inhibition of EGFR and ErbB-2 attenuated cell growth by increasing cell death, and the antibody combination suppressed cell growth to a greater extent than did either antibody alone. In conclusion, EGFR and ErbB-2 regulate ERK-mediated COX-2 expression and their selective inhibition enhanced NS-398-induced cell death. Cooperative inhibition of cell growth by EGFR and ErbB-2 blockade suggests the therapeutic potential of targeting multiple ErbB receptors.

AB - Cyclooxygenase-2 (COX-2) is a transcriptional target and downstream effector of the ErbB-1 (EGFR) and ErbB-2 signaling pathways. We found that anti-EGFR and anti-ErbB-2 antibodies inhibited ERK phosphorylation and downregulated COX-2 protein expression in HCA-7 human colon carcinoma cells. Both antibodies also augmented the cytotoxic effects of the selective COX-2 inhibitor, NS-398. Inhibition of EGFR and ErbB-2 attenuated cell growth by increasing cell death, and the antibody combination suppressed cell growth to a greater extent than did either antibody alone. In conclusion, EGFR and ErbB-2 regulate ERK-mediated COX-2 expression and their selective inhibition enhanced NS-398-induced cell death. Cooperative inhibition of cell growth by EGFR and ErbB-2 blockade suggests the therapeutic potential of targeting multiple ErbB receptors.

KW - Cetuximab

KW - COX-2

KW - EGFR

KW - ErbB-2

KW - NS-398

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=34247581723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247581723&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2006.11.020

DO - 10.1016/j.canlet.2006.11.020

M3 - Article

C2 - 17189670

AN - SCOPUS:34247581723

VL - 251

SP - 237

EP - 246

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -